PTK2 and B-cell chronic lymphocytic leukemia: Importantly, the mean cell viability was not significantly different between 2.5 μM ibrutinib, defactinib, and the 2.5 μM combination, which suggests that the further decrease in CLL migration was due to FAK-dependent migration mechanisms.